• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

    2/14/24 2:27:06 PM ET
    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REPH alert in real time by email
    SC 13G/A 1 sctl13ga.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

     

    Societal CDMO, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

     

    75629F109

    (CUSIP Number)

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     
     

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 10,324,858

     

    6. Shared Voting Power 16,000

     

    7. Sole Dispositive Power 10,324,858
    8. Shared Dispositive Power 16,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 10,340,858

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.9%

     

    12.Type of Reporting Person (See Instructions) IN

     
     

    Item 1.

     

    (a)Name of Issuer

    Societal CDMO, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    1 E. Uwchlan Ave, Suite 112, Exton, PA 19341

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to shares of Common Stock, par value $0.01 per share of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 75629F109
     
     
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    The percentages reported in this Schedule 13G are based on 104,788,222 shares of the Stock outstanding as of November 1, 2023, as reported in the Form 10-Q filed by the Issuer on November 8, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     
     

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

    /s/ Laurence W. Lytton

    Laurence W. Lytton

     

     

     

    Get the next $REPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPH

    DatePrice TargetRatingAnalyst
    10/12/2021Outperform
    William Blair
    More analyst ratings

    $REPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Recro Pharma

      William Blair initiated coverage of Recro Pharma with a rating of Outperform

      10/12/21 7:16:48 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 3:53:17 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 2:27:06 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Recro Pharma Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      8/31/23 11:59:02 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Financials

    Live finance-specific insights

    See more
    • Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

      SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr

      2/22/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Third Quarter 2021 Financial Results

      Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q

      11/9/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

      SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 fro

      11/2/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    SEC Filings

    See more
    • Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/28/23 4:14:11 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Recro Pharma Inc.

      10-Q - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:13:18 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:11:37 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Recro Announces Executive Changes

      MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM

      12/16/20 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      2/6/24 5:31:29 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 6:00:30 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 5:59:39 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

      With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r

      3/21/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Fourth Quarter and Year End 2021 Financial Results

      Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea

      3/1/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

      SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization

      2/23/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care